Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms

Study Identifier
AGN/OPH/DE/002
CT.gov Identifier
NCT00761202
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dry Eye
    • Study Drug
  • A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®
  • Sodium hyaluronate
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * 18 years or over * Contact lens wearer, spectacle wearer or non-spectacle wearer * Mild to severe dry eye symptoms, defined as OSDI score 13 to 100 * Mild to moderate conjunctival staining in each eye and/or mild to moderate corneal staining in each eye * Best corrected visual acuity of 6/9 in each eye
    Exclusion Criteria:
    * Previously used Hylocomod or Optive eyedrops * Systemic allergy or eye allergy * Systemic disease which might have an ocular component and/or interfere with contact lens wear * Autoimmune disease which might have an ocular component and/or interfere with contact lens wear * Systemic medication which might have eye side effects and or interfere with contact lens wear * Eye infection or use of eye medication

    Protocol Summary

    This study evaluates the performance and acceptance of Optive versus Hylocomod eyedrops, when administered for one month to patients with mild to moderate dry eye symptoms, with and without contact lenses.

    Study Locations

    Location
    Status
    Location
    London, London, United Kingdom
    Status
    Not applicable